Lone Bredo Pedersen

Research output

Research output per year 2011 2012 2013 2014 2015 2016 2017 2018 2020 2021 2022 2022

• 28 Journal article
• 3 Letter
• 1 Conference abstract for conference

Research output per year

Research output per year

Search results

• 2022

  Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV

  Klausen, U., Grauslund, J. H., Jørgensen, N. G. D., Ahmad, S. M., Jonassen, M., Weis-Banke, S. E., Martinenaite, E., Pedersen, L. B., Lisle, T. L., Gang, A. O., Enggaard, L., Hansen, M., Holmström, M. O., Met, Ö., Svane, I. M., Niemann, C. U., Pedersen, L. M. & Andersen, M. H., 2022, In: Frontiers in Oncology. 12, p. 1-13 13 p., 1023015.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Immunoglobulin Heavy Chains 100%
  • B-Cell Chronic Lymphocytic Leukemia 81%
  • Vaccination 61%
  • Ligands 54%
  • Vaccines 23%

• Chronic lymphocytic leukaemia clones are detectable decades before diagnosis

  Vojdeman, F. J., Helby, J., Pedersen, L. B., Brieghel, C., Andersen, M. A., Nordestgaard, B. G., Bojesen, S. E. & Niemann, C. U., Feb 2022, In: British Journal of Haematology. 196, 3, p. 784-787 4 p.

  Research output: Contribution to journal › Letter › peer-review

  2 Citations (Scopus)

• Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL

  Husby, S., Bæch-Laursen, C., Eskelund, C. W., Favero, F., Jespersen, J. S., Hutchings, M., Pedersen, L. B., Niemann, C. U., Weischenfeldt, J., Räty, R., Larsen, T. S., Kolstad, A., Jerkeman, M. & Grønbæk, K., Dec 2022, In: Leukemia. 36, 12, p. 2912-2916 5 p.

  Research output: Contribution to journal › Letter › peer-review

  1 Citation (Scopus)
• 2021

  An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma

  Klausen, U., Grønne Dahlager Jørgensen, N., Grauslund, J. H., Munir Ahmad, S., Gang, A. O., Martinenaite, E., Weis-Banke, S. E., Breinholt, M. F., Novotny, G. W., Kjeldsen, J. W., Orebo Holmström, M., Pedersen, L. B., Poulsen, C. B., Hansen, P. B., Met, Ö., Svane, I. M., Niemann, C. U., Pedersen, L. M. & Andersen, M. H., 2021, In: OncoImmunology. 10, 1, 1975889.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Follicular Lymphoma 100%
  • Vaccines 60%
  • Peptides 51%
  • Blood Cells 22%
  • Injection Site Reaction 18%
  3 Citations (Scopus)

• Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3

  Eskelund, C. W., Dimopoulos, K., Kolstad, A., Glimelius, I., Räty, R., Gjerdrum, L. M. R., Sonnevi, K., Josefsson, P., Nilsson-Ehle, H., Bentzen, H. H. N., Fagerli, U. M., Kuittinen, O., Haaber, J., Niemann, C. U., Pedersen, L. B., Larsen, M. T., Geisler, C. H., Hutchings, M., Jerkeman, M. & Grønbæk, K., Jan 2021, In: HemaSphere. 5, 1, p. 1-8 8 p., 510.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Mantle-Cell Lymphoma 100%
  • Bendamustine Hydrochloride 23%
  • Salvage Therapy 18%
  • Recurrence 17%
  • Cytarabine 17%
  12 Citations (Scopus)

• Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

  Agathangelidis, A., Chatzidimitriou, A., Gemenetzi, K., Giudicelli, V., Karypidou, M., Plevova, K., Davis, Z. A., Yan, X-J., Jeromin, S., Schneider, C., Pedersen, L. B., Tschumper, R., Sutton, L. A., Baliakas, P., Scarfò, L., van Gastel, E. J., Armand, M., Tausch, E., Biderman, B., Baer, C., & 63 othersBagnara, D., Navarro, A., de Septenville, A., Guido, V., Mitterbauer-Hohendanner, G., Dimovski, A., Brieghel, C., Lawless, S., Meggendorfer, M., Stranska, K., Ritgen, M., Facco, M., Tresoldi, C., Visentin, A., Patriarca, A., Catherwood, M., Bonello, L., Sudarikov, A., Vanura, K., Roumelioti, M., Skuhrova Francova, H., Moysiadis, T., Veronese, S. M., Giannopoulos, K., Mansouri, L., Karan-Djurasevic, T., Sandaltzopoulos, R., Bödör, C., Fais, F., Kater, A. P., Panovska-Stavridis, I., Rossi, D., Alshemmari, S., Panagiotidis, P., Costeas, P. A., Espinet, B., Antic, D., Foroni, L., Montillo, M., Trentin, L., Stavroyianni, N., Gaidano, G., Francia di Celle, P., Niemann, C. U., Campo, E., Anagnostopoulos, A., Pott, C., Fischer, K., Hallek, M., Oscier, D. G., Stilgenbauer, S., Haferlach, C., Jelinek, D. F., Chiorazzi, N., Pospisilova, S., Lefranc, M-P., Kossida, S., Langerak, A. W., Belessi, C., Davi, F., Rosenquist, R., Ghia, P. & Stamatopoulos, K., 11 Mar 2021, In: Blood. 137, 10, p. 1365-1376 12 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • B-Cell Chronic Lymphocytic Leukemia 100%
  • Heterogeneity 86%
  • Immunoglobulins 35%
  • B-Lymphocytes 31%
  • Gene Rearrangement 15%
• 2020

  Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL

  Eskelund, C. W., Husby, S., Favero, F., Klausen, T. W., Rodriguez-Gonzalez, F. G., Kolstad, A., Pedersen, L. B., Räty, R. K., Geisler, C. H., Jerkeman, M., Weischenfeldt, J. & Grønbæk, K., 28 May 2020, In: Blood. 135, 22, p. 2000-2004 5 p.

  Research output: Contribution to journal › Letter › peer-review

• The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome

  Brieghel, C., da Cunha-Bang, C., Yde, C. W., Schmidt, A. Y., Kinalis, S., Nadeu, F., Andersen, M. A., Jacobsen, L. O., Andersen, M. K., Pedersen, L. B., Delgado, J., Baumann, T., Mattsson, M., Mansouri, L., Rosenquist, R., Campo, E., Nielsen, F. C. & Niemann, C. U., 15 Mar 2020, In: Clinical Cancer Research. 26, 6, p. 1507-1515 9 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • B-Cell Chronic Lymphocytic Leukemia 100%
  • Mutation 52%
  • Genes 21%
  • Biomarkers 20%
  • Aftercare 12%
• 2019

  Deep targeted sequencing of TP53 in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment

  Brieghel, C., Kinalis, S., Yde, C. W., Schmidt, A. Y., Jønson, L., Andersen, M. A., da Cunha-Bang, C., Pedersen, L. B., Geisler, C. H., Nielsen, F. C. & Niemann, C. U., Apr 2019, In: Haematologica. 104, 4, p. 789-796

  Research output: Contribution to journal › Journal article › Research › peer-review

  • B-Cell Chronic Lymphocytic Leukemia 100%
  • High-Throughput Nucleotide Sequencing 90%
  • Gene Frequency 68%
  • Chromosome Deletion 60%
  • Mutation 52%
  23 Citations (Scopus)
• 2018

  Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

  Ahn, I. E., Farooqui, M. Z. H., Tian, X., Valdez, J., Sun, C., Soto, S., Lotter, J., Housel, S., Stetler-Stevenson, M., Yuan, C. M., Maric, I., Calvo, K. R., Nierman, P., Hughes, T. E., Saba, N. S., Marti, G. E., Pittaluga, S., Herman, S. E. M., Niemann, C. U., Pedersen, L. B., & 4 othersGeisler, C. H., Childs, R., Aue, G. & Wiestner, A., 24 May 2018, In: Blood. 131, 21, p. 2357-2366 10 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Ibrutinib 100%
  • PCI 32765 83%
  • B-Cell Chronic Lymphocytic Leukemia 59%
  • Refractory 29%
  • Safety 23%
  150 Citations (Scopus)

• Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

  Jerkeman, M., Eskelund, C. W., Hutchings, M., Räty, R., Wader, K. F., Laurell, A., Toldbod, H., Pedersen, L. B., Niemann, C. U., Dahl, C., Kuitunen, H., Geisler, C. H., Grønbæk, K. & Kolstad, A., 1 Mar 2018, In: The Lancet. Haematology. 5, 3, p. 109-116

  Research output: Contribution to journal › Journal article › Research › peer-review

  • PCI 32765 100%
  • Lenalidomide 89%
  • Mantle-Cell Lymphoma 87%
  • Rituximab 73%
  • Finland 5%
  101 Citations (Scopus)

• Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

  Eskelund, C. W., Albertsson-Lindblad, A., Kolstad, A., Laurell, A., Räty, R., Pedersen, L. B., Geisler, C. H., Jerkeman, M. & Grønbæk, K., Nov 2018, In: Haematologica. 3, 11, p. 541-543 3 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  14 Citations (Scopus)
• 2017

  Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

  Xochelli, A., Baliakas, P., Kavakiotis, I., Agathangelidis, A., Sutton, L-A., Minga, E., Ntoufa, S., Tausch, E., Yan, X-J., Shanafelt, T., Plevova, K., Boudjogra, M., Rossi, D., Davis, Z., Navarro, A., Sandberg, Y., Vojdeman, F. J., Scarfò, L., Stavroyianni, N., Sudarikov, A., & 42 othersVeronese, S., Tzenou, T., Karan-Djurasevic, T., Catherwood, M., Kienle, D., Chatzouli, M., Facco, M., Bahlo, J., Pott, C., Pedersen, L. B., Mansouri, L., Smedby, K. E., Chu, C. C., Giudicelli, V., Lefranc, M-P., Panagiotidis, P., Juliusson, G., Anagnostopoulos, A., Vlahavas, I., Antic, D., Trentin, L., Montillo, M., Niemann, C., Döhner, H., Langerak, A. W., Pospisilova, S., Hallek, M., Campo, E., Chiorazzi, N., Maglaveras, N., Oscier, D. G., Gaidano, G., Jelinek, D. F., Stilgenbauer, S., Chouvarda, I., Darzentas, N., Belessi, C., Davi, F., Hadzidimitriou, A., Rosenquist, R., Ghia, P. & Stamatopoulos, K., Sep 2017, In: Clinical Cancer Research. 23, 17, p. 5292-5301

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Immunogenetics 100%
  • B-Cell Chronic Lymphocytic Leukemia 80%
  • B-Lymphocytes 21%
  • Immunoglobulin G 21%
  • Immunoglobulin M 16%
  25 Citations (Scopus)

• Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years

  Kolstad, A., Pedersen, L. B., Eskelund, C. W., Husby, S., Grønbæk, K., Jerkeman, M., Laurell, A., Räty, R., Elonen, E., Andersen, N. S., Brown, P. D., Kimby, E., Bentzen, H., Sundström, C., Ehinger, M., Karjalainen-Lindsberg, M-L., Delabie, J., Ralfkiær, E., Fagerli, U-M., Nilsson-Ehle, H., & 5 othersLauritzsen, G. F., Kuittinen, O., Niemann, C., Geisler, C. H. & Nordic Lymphoma Group, 2017, In: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 23, 3, p. 428-435

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Mantle-Cell Lymphoma 100%
  • Rituximab 83%
  • Residual Neoplasm 81%
  • Stem Cell Transplantation 80%
  • Recurrence 43%
  52 Citations (Scopus)

• Patients with Chronic Lymphocytic Leukemia Belonging to the B-Cell Receptor Stereotypy Subset #2 Have Long Progression Free Survival after Chemo- or Chemoimmunotherapy in the HOVON68 Trial.

  Vojdeman, F. J., Pedersen, L. B., te Raa, G. D., Juvonen, V., Norden, Y., Tjønnfjord, G. E., Kimby, E., Itälä-Remes, M., Langerak, A. W., Evers, L. M., Zenz, T., van Oers, M., Geisler, C., Kater, A. P. & Niemann, C., 7 Dec 2017.

  Research output: Contribution to conference › Conference abstract for conference › Research › peer-review

• TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

  Eskelund, C. W., Dahl, C., Hansen, J. W., Westman, M., Kolstad, A., Pedersen, L. B., Montano-Almendras, C. P., Husby, S., Freiburghaus, C., Ek, S., Pedersen, A., Niemann, C., Räty, R., Brown, P., Geisler, C. H., Andersen, M. K., Guldberg, P., Jerkeman, M. & Grønbæk, K., 2017, In: Blood. 130, 17, p. 1903-1910

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Mantle-Cell Lymphoma 100%
  • Mutation 64%
  • Standard of Care 37%
  • Cytarabine 31%
  • Rituximab 20%
  243 Citations (Scopus)
• 2016

  15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau

  Eskelund, C. W., Kolstad, A., Jerkeman, M., Räty, R., Laurell, A., Eloranta, S., Smedby, K. E., Husby, S., Pedersen, L. B., Andersen, N. S., Eriksson, M., Kimby, E., Bentzen, H., Kuittinen, O., Lauritzsen, G. F., Nilsson-Ehle, H., Ralfkiaer, E., Ehinger, M., Sundström, C., Delabie, J., & 7 othersKarjalainen-Lindsberg, M-L., Workman, C. T., Garde, C., Elonen, E., Brown, P., Grønbaek, K. & Geisler, C. H., Nov 2016, In: British Journal of Haematology. 175, 3, p. 410-418 9 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Mantle-Cell Lymphoma 100%
  • Survival 42%
  • Cytarabine 21%
  • Rituximab 20%
  • Stem Cell Transplantation 20%
  150 Citations (Scopus)

• Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors

  Sutton, L-A., Young, E., Baliakas, P., Hadzidimitriou, A., Moysiadis, T., Plevova, K., Rossi, D., Kminkova, J., Stalika, E., Pedersen, L. B., Malcikova, J., Agathangelidis, A., Davis, Z., Mansouri, L., Scarfò, L., Boudjoghra, M., Navarro, A., Muggen, A. F., Yan, X-J., Nguyen-Khac, F., & 16 othersLarrayoz, M., Panagiotidis, P., Chiorazzi, N., Niemann, C. U., Belessi, C., Campo, E., Strefford, J. C., Langerak, A. W., Oscier, D., Gaidano, G., Pospisilova, S., Davi, F., Ghia, P., Stamatopoulos, K., Rosenquist, R. & ERIC, the European Research Initiative on CLL, Aug 2016, In: Haematologica. 101, 8, p. 959-67 9 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • B-Cell Chronic Lymphocytic Leukemia 100%
  • B-Lymphocytes 72%
  • Mutation 52%
  • Genes 37%
  • Immunoglobulin Genes 29%
  55 Citations (Scopus)

• Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4

  Albertsson-Lindblad, A., Kolstad, A., Laurell, A., Räty, R., Grønbæk, K., Sundberg, J., Pedersen, L. B., Ralfkiær, E., Karjalainen-Lindsberg, M-L., Sundström, C., Ehinger, M., Geisler, C. & Jerkeman, M., 27 Jun 2016, In: Blood. 128, 14, p. 1814-1820

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Lenalidomide 100%
  • Bendamustine Hydrochloride 85%
  • Mantle-Cell Lymphoma 72%
  • Rituximab 60%
  • Lymphoma 46%
  65 Citations (Scopus)
• 2015

  Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

  Farooqui, M. Z. H., Valdez, J., Martyr, S., Aue, G., Saba, N., Niemann, C. U., Herman, S. E. M., Tian, X., Marti, G., Soto, S., Hughes, T. E., Jones, J., Lipsky, A., Pittaluga, S., Stetler-Stevenson, M., Yuan, C., Lee, Y. S., Pedersen, L. B., Geisler, C. H., Calvo, K. R., & 5 othersArthur, D. C., Maric, I., Childs, R., Young, N. S. & Wiestner, A., Feb 2015, In: Lancet Oncology. 16, 2, p. 169-76 8 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • PCI 32765 100%
  • B-Cell Chronic Lymphocytic Leukemia 71%
  • Lymphocytosis 7%
  • National Institutes of Health (U.S.) 6%
  • National Heart, Lung, and Blood Institute (U.S.) 4%
  315 Citations (Scopus)

• miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator

  Husby, S., Ralfkiaer, U., Garde, C., Zandi, R., Ek, S., Kolstad, A., Jerkeman, M., Laurell, A., Räty, R., Pedersen, L. B., Pedersen, A., Ehinger, M., Sundström, C., Karjalainen-Lindsberg, M-L., Delabie, J., Clasen-Linde, E., Brown, P., Cowland, J. B., Workman, C., Geisler, C. H., & 1 othersGrønbæk, K., 23 Apr 2015, In: Blood. 125, 17, p. 2669-77 9 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Mantle-Cell Lymphoma 100%
  • MicroRNA 94%
  • MicroRNAs 35%
  • Microarrays 16%
  • Progression-Free Survival 7%
  43 Citations (Scopus)

• Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations

  Baliakas, P., Agathangelidis, A., Hadzidimitriou, A., Sutton, L-A., Minga, E., Tsanousa, A., Scarfò, L., Davis, Z., Yan, X-J., Shanafelt, T., Plevova, K., Sandberg, Y., Vojdeman, F. J., Boudjogra, M., Tzenou, T., Chatzouli, M., Chu, C. C., Veronese, S., Gardiner, A., Mansouri, L., & 28 othersSmedby, K. E., Pedersen, L. B., Moreno, D., Van Lom, K., Giudicelli, V., Francova, H. S., Nguyen-Khac, F., Panagiotidis, P., Juliusson, G., Angelis, L., Anagnostopoulos, A., Lefranc, M-P., Facco, M., Trentin, L., Catherwood, M., Montillo, M., Geisler, C. H., Langerak, A. W., Pospisilova, S., Chiorazzi, N., Oscier, D., Jelinek, D. F., Darzentas, N., Belessi, C., Davi, F., Ghia, P., Rosenquist, R. & Stamatopoulos, K., 29 Jan 2015, In: Blood. 125, 5, p. 856-9 4 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • B-Cell Chronic Lymphocytic Leukemia 100%
  • Immunoglobulins 83%
  • Genes 15%
  • B-Lymphocytes 14%
  • Therapeutics 3%
  63 Citations (Scopus)
• 2014

  Continuous professional development for GPs: experience from Denmark

  Kjaer, N. K., Steenstrup, A. P., Pedersen, L. B. & Halling, A., Jul 2014, In: Postgraduate Medical Journal. 90, 1065, p. 383-7 5 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Denmark 100%
  • General Practitioners 86%
  • Psychological Burnout 31%
  • Focus Groups 25%
  • Psychological Practice 13%
  23 Citations (Scopus)

• Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study

  Herman, S. E. M., Niemann, C. U., Farooqui, M., Jones, J., Mustafa, R. Z., Lipsky, A., Saba, N., Martyr, S., Soto, S., Valdez, J. G., Gyamfi, J. A., Maric, I., Calvo, K. R., Pedersen, L. B., Geisler, C. H., Liu, D., Marti, G. E., Aue, G. & Wiestner, A., Nov 2014, In: Leukemia. 28, 11, p. 2188-96 9 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • PCI 32765 100%
  • Lymphocytosis 87%
  • Lymphocyte Count 73%
  • B-Cell Chronic Lymphocytic Leukemia 71%
  • Blood Viscosity 28%
  142 Citations (Scopus)

• Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

  Kolstad, A., Laurell, A., Jerkeman, M., Grønbæk, K., Elonen, E., Räty, R., Pedersen, L. B., Loft, A., Bogsrud, T. V., Kimby, E., Hansen, P. B., Fagerli, U-M., Nilsson-Ehle, H., Lauritzsen, G. F., Lehmann, A. K., Sundstrom, C., Karjalainen-Lindsberg, M-L., Ralfkiaer, E., Ehinger, M., Delabie, J., & 7 othersBentzen, H., Schildt, J., Kostova-Aherdan, K., Frederiksen, H., Brown, P. D. N., Geisler, C. H. & Nordic Lymphoma Group, 8 May 2014, In: Blood. 123, 19, p. 2953-9 7 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • ibritumomab tiuxetan 100%
  • Cytarabine 98%
  • Cyclophosphamide 85%
  • Mantle-Cell Lymphoma 79%
  • Positron 70%
  80 Citations (Scopus)

• Silenced B-cell receptor response to autoantigen in a poor-prognostic subset of chronic lymphocytic leukemia

  Bergh, A-C., Evaldsson, C., Pedersen, L. B., Geisler, C., Stamatopoulos, K., Rosenquist, R. & Rosén, A., Nov 2014, In: Haematologica. 99, 11, p. 1722-30 9 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • To autoantigen 100%
  • B-Cell Chronic Lymphocytic Leukemia 72%
  • B-Lymphocytes 52%
  • oxidized low density lipoprotein 25%
  • Immunoglobulin M 22%
  8 Citations (Scopus)
• 2013

  Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2

  Strefford, J. C., Sutton, L-A., Baliakas, P., Agathangelidis, A., Malčíková, J., Plevova, K., Scarfó, L., Davis, Z. J., Stalika, E., Cortese, D., Cahill, N., Pedersen, L. B., di Celle, P. F., Tzenou, T., Geisler, C., Panagiotidis, P., Langerak, A. W., Chiorazzi, N., Pospisilova, S., Oscier, D., & 6 othersDavi, F., Belessi, C., Mansouri, L., Ghia, P., Stamatopoulos, K. & Rosenquist, R., Nov 2013, In: Leukemia. 27, 11, p. 2196-9 4 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • B-Cell Chronic Lymphocytic Leukemia 100%
  • Mutation 52%
  • Mutation Rate 49%
  • Genes 37%
  • B-Lymphocytes 36%
  88 Citations (Scopus)

• Molecular characterization of neoplastic and normal "sister" lymphoblastoid B-cell lines from chronic lymphocytic leukemia

  Lanemo Myhrinder, A., Hellqvist, E., Bergh, A-C., Jansson, M., Nilsson, K., Hultman, P., Jonasson, J., Buhl, A. M., Bredo Pedersen, L., Jurlander, J., Klein, E., Weit, N., Herling, M., Rosenquist, R. & Rosén, A., Aug 2013, In: Leukemia and Lymphoma. 54, 8, p. 1769-79 11 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • B-Cell Chronic Lymphocytic Leukemia 100%
  • Siblings 86%
  • Cell Line 55%
  • B-Lymphocytes 36%
  • DNA 26%
  12 Citations (Scopus)
• 2012

  Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity

  Kostareli, E., Gounari, M., Janus, A., Murray, F., Brochet, X., Giudicelli, V., Pospisilova, S., Oscier, D., Foroni, L., di Celle, P. F., Tichy, B., Pedersen, L. B., Jurlander, J., Ponzoni, M., Kouvatsi, A., Anagnostopoulos, A., Thompson, K., Darzentas, N., Lefranc, M-P., Belessi, C., & 4 othersRosenquist, R., Davi, F., Ghia, P. & Stamatopoulos, K., 2012, In: Leukemia. 26, 5, p. 1127-31 5 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  54 Citations (Scopus)

• Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur

  Geisler, C. H., Kolstad, A., Laurell, A., Jerkeman, M., Räty, R., Andersen, N. S., Pedersen, L. B., Eriksson, M., Nordström, M., Kimby, E., Bentzen, H., Kuittinen, O., Lauritzsen, G. F., Nilsson-Ehle, H., Ralfkiaer, E., Ehinger, M., Sundström, C., Delabie, J., Karjalainen-Lindsberg, M-L., Brown, P., & 2 othersElonen, E. & Nordic Lymphoma Group, 2012, In: British Journal of Haematology. 158, 3, p. 355-62 8 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Mantle-Cell Lymphoma 100%
  • Stem Cells 56%
  • Recurrence 43%
  • Survival 42%
  • Progression-Free Survival 34%
  238 Citations (Scopus)

• Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies

  Agathangelidis, A., Darzentas, N., Hadzidimitriou, A., Brochet, X., Murray, F., Yan, X-J., Davis, Z., van Gastel-Mol, E. J., Tresoldi, C., Chu, C. C., Cahill, N., Giudicelli, V., Tichy, B., Pedersen, L. B., Foroni, L., Bonello, L., Janus, A., Smedby, K., Anagnostopoulos, A., Merle-Beral, H., & 16 othersLaoutaris, N., Juliusson, G., di Celle, P. F., Pospisilova, S., Jurlander, J., Geisler, C., Tsaftaris, A., Lefranc, M-P., Langerak, A. W., Oscier, D. G., Chiorazzi, N., Belessi, C., Davi, F., Rosenquist, R., Ghia, P. & Stamatopoulos, K., 2012, In: Blood. 119, 19, p. 4467-75 9 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • B-Cell Chronic Lymphocytic Leukemia 100%
  • B-Lymphocytes 72%
  • Time 33%
  • Therapeutics 15%
  • Cluster Analysis 14%
  316 Citations (Scopus)
• 2011

  Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases

  Hadzidimitriou, A., Agathangelidis, A., Darzentas, N., Murray, F., Delfau-Larue, M-H., Pedersen, L. B., Lopez, A. N., Dagklis, A., Rombout, P., Beldjord, K., Kolstad, A., Dreyling, M. H., Anagnostopoulos, A., Tsaftaris, A., Mavragani-Tsipidou, P., Rosenwald, A., Ponzoni, M., Groenen, P., Ghia, P., Sander, B., & 7 othersPapadaki, T., Campo, E., Geisler, C., Rosenquist, R., Davi, F., Pott, C. & Stamatopoulos, K., 2011, In: Blood. 118, 11, p. 3088-95 8 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Immunogenetics 100%
  • Mantle-Cell Lymphoma 98%
  • Mutation 64%
  • Antigen 63%
  • Clonogenic 58%
  136 Citations (Scopus)